Daiichi Sankyo Company, Limited

4568

JP3475350009

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 06:30:00 13/02/2026 GMT			5-day change	1st Jan Change
2,937.50 ^JPY	+1.08%		+2.39%	-12.26%

02-03	AstraZeneca Says Breast Cancer Treatment Granted US FDA Priority Review	MT
02-03	Daiichi Sankyo And AstraZeneca Receive Priority Review For DATROWAY For Treatment Of Unresectable Or Metastatic Triple Negative Breast Cancer In The U.S	CI

Tranche Update on Daiichi Sankyo Company, Limited's Equity Buyback Plan announced on April 25, 2025.

Published on 01/05/2026 at 08:06 am GMT

S&P Capital IQ

DAIICHI SANKYO COMPANY, LIMITED

+1.08%

From October 1, 2025 to December 31, 2025, the company has repurchased 0 shares, representing 0% for ¥0 million. With this, the company has completed the repurchase of 0 shares, representing 0% for ¥0 million under the buyback announced on April 25, 2025.

Latest news about Daiichi Sankyo Company, Limited

02-03	AstraZeneca Says Breast Cancer Treatment Granted US FDA Priority Review	MT
02-03	Daiichi Sankyo And AstraZeneca Receive Priority Review For DATROWAY For Treatment Of Unresectable Or Metastatic Triple Negative Breast Cancer In The U.S	CI
02-03	AG Barr adds drink brands; Filtronic profit falls	AN
02-02	Nikkei slides on tech, resources sell-off despite weaker yen	RE
01-30	Daiichi Sankyo Company, Limited, Q3 2026 Earnings Call, Jan 30, 2026
01-30	Daiichi Sankyo's Nine-Month Profit Rises 4%	MT
01-30	Daiichi Sankyo Company, Limited Reports Earnings Results for the Nine Months Ended December 31, 2025	CI
01-28	Berenberg Ups AstraZeneca Price Target on Datroway's Sales Potential in Lung Cancer	MT
01-22	Daiichi and AstraZeneca's Enhertu wins sixth approval in China	AN
01-22	Daiichi Sankyo Appoints Veronika Rozehnal, Ph.D., as Head of Translational Research Center Europe	CI
01-20	AstraZeneca, Daiichi Sankyo Say European Medicines Agency Validates Enhertu Application for Breast Cancer	MT
01-19	Daiichi Sankyo and AstraZeneca cheer EU milestone for cancer drug	AN
01-19	European Medicines Agency Validated in the EU as First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer	CI
01-07	Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for Nanflyta®? Commercialization in Central and Eastern Europe	CI
01-05	Tranche Update on Daiichi Sankyo Company, Limited's Equity Buyback Plan announced on April 25, 2025.	CI

Chart Daiichi Sankyo Company, Limited

Duration

Period

4568: Dynamic Chart

Company Profile

Daiichi Sankyo Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of pharmaceuticals. The Company is involved in the research, development, manufacture and sale of pharmaceuticals, as well as the provision of intermediates and basic materials for pharmaceutical producing in Japan, the United States, Europe and other markets. The Company is also engaged in the research, development, manufacture and sale of over-the-counter drugs and vaccines, the provision of administrative services such as human resources and accounting services, real estate leasing and insurance agency business.

Employees

19,765

Sector

Pharmaceuticals

Calendar

08-04 - Q1 2026 Earnings Release (Projected)

More about the company